Masakatsu Tsuji

3.4k total citations
49 papers, 2.8k citations indexed

About

Masakatsu Tsuji is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Masakatsu Tsuji has authored 49 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pharmacology, 41 papers in Molecular Medicine and 11 papers in Epidemiology. Recurrent topics in Masakatsu Tsuji's work include Antibiotic Resistance in Bacteria (41 papers), Antibiotics Pharmacokinetics and Efficacy (41 papers) and Pneumonia and Respiratory Infections (8 papers). Masakatsu Tsuji is often cited by papers focused on Antibiotic Resistance in Bacteria (41 papers), Antibiotics Pharmacokinetics and Efficacy (41 papers) and Pneumonia and Respiratory Infections (8 papers). Masakatsu Tsuji collaborates with scholars based in Japan, United States and Canada. Masakatsu Tsuji's co-authors include Yoshinori Yamano, Roger Echols, Rio Nakamura, Akinobu Ito, Takafumi Sato, Daniel F. Sahm, Meredith Hackel, James A. Karlowsky, Shuhei Matsumoto and Toru Nishikawa and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy and European Journal of Medicinal Chemistry.

In The Last Decade

Masakatsu Tsuji

49 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masakatsu Tsuji Japan	24	2.4k	1.8k	776	592	478	49	2.8k
Yoshinori Yamano Japan	30	2.9k 1.2×	2.2k 1.2×	958 1.2×	706 1.2×	757 1.6×	101	3.6k
Ilias Karaiskos Greece	30	3.0k 1.2×	2.1k 1.1×	771 1.0×	1.4k 2.3×	323 0.7×	56	3.6k
Phillip J. Bergen Australia	29	2.2k 0.9×	1.6k 0.9×	380 0.5×	893 1.5×	655 1.4×	79	3.0k
Takafumi Sato Japan	15	1.5k 0.6×	1.0k 0.6×	412 0.5×	354 0.6×	433 0.9×	34	1.9k
Laura Zamorano Spain	30	2.3k 1.0×	935 0.5×	457 0.6×	494 0.8×	1.2k 2.6×	67	2.9k
Gabriel Cabot Spain	33	2.6k 1.1×	957 0.5×	564 0.7×	450 0.8×	1.4k 3.0×	57	3.1k
Samuel K. Bouchillon United States	31	1.9k 0.8×	1.1k 0.6×	825 1.1×	683 1.2×	267 0.6×	51	2.6k
Magdalena A. Taracila United States	33	2.8k 1.2×	1.5k 0.8×	507 0.7×	848 1.4×	808 1.7×	75	3.5k
Bartolomé Moyá Spain	32	2.7k 1.1×	1.1k 0.6×	446 0.6×	586 1.0×	1.3k 2.8×	51	3.2k
Marina Warner United Kingdom	25	2.0k 0.8×	1.1k 0.6×	458 0.6×	563 1.0×	457 1.0×	44	2.5k

Countries citing papers authored by Masakatsu Tsuji

Since Specialization

Citations

This map shows the geographic impact of Masakatsu Tsuji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masakatsu Tsuji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masakatsu Tsuji more than expected).

Fields of papers citing papers by Masakatsu Tsuji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masakatsu Tsuji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masakatsu Tsuji. The network helps show where Masakatsu Tsuji may publish in the future.

Co-authorship network of co-authors of Masakatsu Tsuji

This figure shows the co-authorship network connecting the top 25 collaborators of Masakatsu Tsuji. A scholar is included among the top collaborators of Masakatsu Tsuji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masakatsu Tsuji. Masakatsu Tsuji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aoki, Toshiaki, Hidenori Yoshizawa, Kenji Yamawaki, et al.. (2018). Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship. European Journal of Medicinal Chemistry. 155. 847–868. 133 indexed citations

Karlowsky, James A., Meredith Hackel, Masakatsu Tsuji, et al.. (2018). In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. International Journal of Antimicrobial Agents. 53(4). 456–466. 127 indexed citations

Lee, Yuarn‐Jang, et al.. (2018). In vitroactivities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistantPseudomonas aeruginosaandAcinetobacter baumannii, andStenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. Journal of Antimicrobial Chemotherapy. 74(2). 380–386. 85 indexed citations

Kazmierczak, Krystyna M., Masakatsu Tsuji, Mark G. Wise, et al.. (2018). In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). International Journal of Antimicrobial Agents. 53(2). 177–184. 157 indexed citations

Ghazi, Islam M., Marguerite L. Monogue, Masakatsu Tsuji, & David P. Nicolau. (2018). Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant <b><i>Pseudomonas aeruginosa</i></b>. Pharmacology. 101(5-6). 278–284. 38 indexed citations

Hackel, Meredith, Masakatsu Tsuji, Yoshinori Yamano, et al.. (2017). In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrobial Agents and Chemotherapy. 62(2). 186 indexed citations

Matsumoto, Shuhei, Jennifer L. Hoover, Rio Nakamura, et al.. (2017). Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics. Antimicrobial Agents and Chemotherapy. 61(9). 90 indexed citations

Yamano, Yoshinori, Rio Nakamura, Takafumi Sato, Masakatsu Tsuji, & Roger Echols. (2017). Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions. Open Forum Infectious Diseases. 4(suppl_1). S476–S477. 1 indexed citations

Monogue, Marguerite L., Masakatsu Tsuji, Yoshinori Yamano, Roger Echols, & David P. Nicolau. (2017). Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 61(11). 90 indexed citations

10.

Ito, Akinobu, Takafumi Sato, Miki Takemura, et al.. (2017). In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy. 62(1). 291 indexed citations

11.

Ghazi, Islam M., Marguerite L. Monogue, Masakatsu Tsuji, & David P. Nicolau. (2017). Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. International Journal of Antimicrobial Agents. 51(2). 206–212. 45 indexed citations

12.

Huband, Michael D., et al.. (2017). Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller–Hinton broth using a CLSI M23-A4 multi-laboratory study design. Diagnostic Microbiology and Infectious Disease. 88(2). 198–200. 32 indexed citations

13.

Ito, Akinobu, Toru Nishikawa, Shuhei Matsumoto, et al.. (2016). Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 60(12). 7396–7401. 245 indexed citations

14.

Ito, Akinobu, Naoki Kohira, Samuel K. Bouchillon, et al.. (2015). In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 71(3). 670–677. 149 indexed citations

15.

Horiyama, Tsukasa, et al.. (2015). Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli. Journal of Infection and Chemotherapy. 21(5). 381–384. 2 indexed citations

16.

Tsuji, Masakatsu, Takahiro Yamaguchi, Rio Nakamura, et al.. (2015). S-649266, A Novel Siderophore Cephalosporin: In Vitro Activity Against Gram-Negative Bacteria Isolated in Japan Including Carbapenem-Resistant Strains. Open Forum Infectious Diseases. 2(suppl_1). 778–778. 2 indexed citations

17.

Kodama, Makoto, Ryu Yoshida, Mitsutaka Kitano, et al.. (2014). The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice. Antiviral Research. 109. 110–115. 6 indexed citations

18.

Suzuki, Hideyuki, et al.. (2013). Potent Oxazolidinone Antibacterials with Heteroaromatic C-Ring Substructure. ACS Medicinal Chemistry Letters. 4(11). 1074–1078. 22 indexed citations

19.

Tsuji, Masakatsu. (2003). Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models. Journal of Antimicrobial Chemotherapy. 51(2). 353–359. 21 indexed citations

20.

Tsuji, Masakatsu, Yoshikazu Ishii, Akira Ohno, Shuichi Miyazaki, & Keizo Yamaguchi. (1998). In Vitro and In Vivo Antibacterial Activities of S-4661, a New Carbapenem. Antimicrobial Agents and Chemotherapy. 42(1). 94–99. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact